secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPIANT PHARMACEUTICALS, INC. (—)
CIK:        0001385508
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001385508-23-000051
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 5.01, 3.01, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opiant Pharmaceuticals acquired by Indivior Inc. for $20/share plus CVR; stock delisted
--------------------------------------------------------------------------------

- Merger closed March 2, 2023; Opiant stockholders approved on March 1, 2023.
- Each share converted into $20 cash plus one CVR with up to $8 additional based on nalmefene sales milestones.
- Opiant common stock suspended from Nasdaq prior to open on March 2; delisting requested.
- All directors and officers ceased; Dr. Phil Skolnick to provide transition services for three months.
- Note purchase agreement terminated and repaid in full; related liens released.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385508/000138550823000051/0001385508-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385508/000138550823000051/opnt-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001385508-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer